Latest Lead News

Vita Resources NL, formerly Bastion Minerals, has advanced its Canadian and Australian projects with new exploration agreements and acquisitions, supported by a recent capital raise. The company is gearing up for significant exploration activities in 2026 under its refreshed corporate identity.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Beetaloo Energy has secured key regulatory approvals and approved the Final Investment Decision for its Carpentaria Pilot Project, setting the stage for first gas sales from EP187 in late 2026.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

Entropy Neurodynamics has successfully enrolled and dosed the first patient in its pioneering clinical trial of TRP-8803, an intravenous psilocin formulation targeting Binge Eating Disorder, while securing $6.1 million in new funding to accelerate development.

Yugo Metals has made promising progress with diamond drilling at its Sinjakovo project, intersecting silver-zinc-lead mineralisation, while securing $3.5 million in new funding and expanding its investor reach through a dual listing in Germany.

Neurotech International has secured a Rare Pediatric Disease Designation from the FDA for its lead drug NTI164 targeting Rett syndrome, alongside publishing promising clinical data and raising $8.7 million to fuel further development.

Odyssey Gold has reported strong drilling results at its Tuckanarra Gold Project, confirming high-grade gold mineralisation and extensions below existing resources. The company also secured $9 million in new funding to support ongoing development.

Percheron Therapeutics has reported encouraging safety and efficacy signals from its HMBD-002 phase I trial, and outlined an innovative modular phase II trial design targeting multiple cancers in 2026.

Lightning Minerals has confirmed extensive gold and base metal mineralisation along a 12km strike at its Mt Turner Project, Queensland, following a successful inaugural drill program. The company secured A$2.5 million to fund an ambitious Phase 2 drilling campaign set for early 2026.

Australian United Investment Company Limited (AUI) has entered into a binding agreement to merge with Diversified United Investment Limited (DUI) through a share exchange scheme, aiming to enhance liquidity, reduce costs, and maintain dividends.